Ad
related to: approved gene therapies for hemophilia- Education Specialists
Find a disease education
specialist near you.
- Active Lifestyle Benefits
Why moving more is a good move.
Bleeding disorders and exercise.
- Patient Resources
Find helpful resources and videos
for rare bleeding disorders.
- Blood Clots & Coagulation
A quick look at bleeding disorders.
Learn about the basics.
- Education Specialists
Search results
Results from the WOW.Com Content Network
U.S. officials on Thursday approved drugmaker BioMarin's gene therapy for the most common form of hemophilia, a $2.9 million infused treatment that can significantly reduce dangerous bleeding ...
The gene therapy will compete with Australia-based CSL Behring’s Hemgenix, a similar treatment that won FDA approval for hemophilia B in 2022. That drug has a similar list price of $3.5 million ...
By Nathan Gomes (Reuters) -The U.S. Food and Drug Administration on Thursday approved BioMarin Pharmaceutical's gene therapy for severe hemophilia A, the company said, giving patients with the ...
Voretigene neparvovec is an approved gene therapy to treat Leber's hereditary optic neuropathy. [94]: 1354 alipogene tiparvovec, a treatment for pancreatitis caused by a genetic condition, and Zolgensma for the treatment of spinal muscular atrophy both use an adeno-associated virus vector. [78]: 2647
Etranacogene dezaparvovec (Hemgenix): AAV-based treatment for hemophilia B [10] Exagamglogene autotemcel (Casgevy): treatment for sickle cell disease. [11] Gendicine: treatment for head and neck squamous cell carcinoma; Idecabtagene vicleucel (Abecma): treatment for multiple myeloma [12] Lovotibeglogene autotemcel (Lyfgenia): treatment for ...
Valoctocogene roxaparvovec, sold under the brand name Roctavian, is a gene therapy used for the treatment of hemophilia A. [ 1 ] [ 3 ] It was developed by BioMarin Pharmaceutical . [ 4 ] [ 5 ] [ 6 ] Valoctocogene roxaparvovec is made of a virus (AAV5) that has been modified to contain the gene for factor VIII, which is lacking in people with ...
If approved, Pfizer's hemophilia A gene therapy will compete with BioMarin Pharmaceutical's one-time treatment Roctavian, which was approved in the U.S. last year and is priced at $2.9 million.
Fidanacogene elaparvovec, previously known by its study ID number SPK-9001, [12] is a gene therapy for the treatment of hemophilia B. It was developed by Spark in partnership with Pfizer . Fidanacogene elaparvovec is an adeno-associated viral vector which is designed to transfer a working copy of the Factor IX gene into the livers of patients ...
Ad
related to: approved gene therapies for hemophilia